Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: A pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 6, 2007, Pages 2100-2106

  Feuillan, Penelope ^a,b   Calis, Karim ^b   Hill, Suvimol ^b   Shawker, Thomas ^b   Robey, Pamela Gehron ^c   Collins, Michael T ^c  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; ESTRADIOL; GONADORELIN AGONIST; HYDROXYPROLINE; LETROZOLE; OSTEOCALCIN; PYRIDINOLINE;

ABDOMINAL PAIN; ALBRIGHT SYNDROME; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE AGE; BONE METABOLISM; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GROWTH RATE; HUMAN; HYDROXYPROLINE URINE LEVEL; LAPAROSCOPIC SURGERY; NAUSEA; ORGAN SIZE; OVARY; OVARY CYST; OVARY HYPERTROPHY; PILOT STUDY; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; UNPLEASANT SENSATION; UTERUS; VAGINA BLEEDING; VIRUS INFECTION; VOMITING;

EID: 34347217118     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2350     Document Type: Article

References (29)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Speigel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
2. Lumbroso S, Paris F, Sultan C 2004 Activating Gsα mutations: analysis of 113 patients with signs of McCune-Albright syndrome - a European collaborative study. J Clin Endocrinol Metab 89:2107-2113
3. Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, Cutler Jr GB 1984 Variable response to a long-acting agonist of luteinizing hormone releasing hormone in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 59:801-805
4. Feuillan PP, Jones J, Cutler Jr GB 1998, Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 77:647-651
5. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Biance P, Wientroub S, Robey P, Collins M 2002 Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 87:5104-5112
6. Riminucci M, Liu B, Corsi A, Shenker A, Speigel AM, Robey PG 1999 The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gsα gene: site-specific patterns and recurrent histologic hallmarks. J Pathol 187:249-258
7. Leet AI, Chebli C, Kushner H, Chen C, Kelly M, Brillante B, Robey PG, Bianco P, Wientroub S, Collins MT 2004 Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 19:571-577
8. Isaia GC, Lala R, Defillipi C, Matarazzo P, Andreo M, Roggia C, Priolo G, deSanctis C 2002 Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Calcif Tiss Int 71:121-128
9. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen C 2005 An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 20:219-226
10. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG 2001 Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806-813
11. Kaplan FS, Fallon MD, Boden SD, Schmidt R, Senior M, Haddad JG 1988 Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Albright syndrome). N Engl J Med 319:421-425
12. Osada H, Sakamoto R, Seki K, Sekiya S 2005 Accelerated bone turnover in pregnant women with McCune-Albright syndrome. Gynecol Obstet Invest 60:102-107
13. Nunez SB, Calis K, Cutler Jr GB, Jones J, Feuillan, PP 2003 Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 88:5730-5733
14. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou H-C, Pescovitz OH, and the McCune-Albright Study Group 2003 Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 143:60-66
15. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R 1990 Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new, nonsteroidal aromatase inhibitor. J Steroid Biochem Mol Biol 37:1021-1027
16. Novartis Pharmaceuticals Corp. 2006 Femara: adverse reactions. Physicians' Desk Reference. Montvale, NJ: Thomson PDR (www.femara.com/pdf/ FemaraPPI.pdf)
17. Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P 2003 Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Mineral Res 18:1235-1246
18. Sample WF, Lippe BM, Gypes MT 1977 Grey scale ultrasonography of the normal female pelvis. Radiology 125:477-483
19. Greulich WW, Pyle SI 1950 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, CA: Stanford University Press
20. Walton RJ, Bijvoet OLM 1977 A simple slide rule method for the assessment of renal tubular reabsorption of phosphate in man. Clin Chim Acta 81:273-276
21. Marfil F, Pineau V, Sioufi A, Godbillon J 1996 High-performance liquid chromatography of the aromatase inhibitor letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J Chromatog 683:251-258
22. Pfister CU, Martoni A, Zamagni C, Lelli G, DeBraud F, Souppart C, Duval M, Hornberger U 2001 Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 22:191-197
23. Levine MA 2003 Biochemical markers of bone metabolism: application to understanding bone remodeling in children and adolescents. J Pediatr Endocrinol Metab 16:661-672
24. Van Coeverden SCCM, Netelenbos JC, de Ridder CM, Roos JC, Popp-Snidjers C, Delemarre-van de Waal HA 2002 Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 57:107-116
25. Blumsohn A, Hannon RA, Wrate R, Barton J, Al-Dehaimi AW, Colwell A, Eastell R 1994 Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf) 40:663-670
26. Pfeffer S, Molina E, Feuillan P, Simon T 1990 McCune-Albright syndrome: the patterns of scintigraphic abnormalities. J Nucl Med 31:1474-1478
27. Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT 2006 Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 91:2960-2966
28. Al-Fadhli R, Sylvestre C, Buckett W, Tan SL, Tulandi T 2006 A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 85:161-164
29. deZiegler D 2003 The dawning of the non-cancer uses of aromatase inhibitors in gynaecology. Hum Rep 18:1598-1602